If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
118
results.
Updated on
24/12/2025 [07:13:00]
Results 100 to 118 of 118
Absstract of: US2025333485A1
This disclosure provides anti-SARS-COV-2 antibodies or antigen-binding fragments thereof targeting the N-terminal domain (NTD) of the spike(S) protein. The disclosed anti-SARS-COV-2 antibodies or antigen-binding fragments thereof have broadly neutralizing activities against several SARS-COV-2 variants of concern. The disclosed anti-SARS-COV-2 antibodies represent a therapeutic strategy in protecting from SARS-COV-2 infections.
Absstract of: US2025333806A1
Disclosed are compositions, assays, methods, diagnostic methods, kits and diagnostic kits for the specific and differential detection of SARS-CoV-2, including SARS-CoV-2 variants, or other coronaviruses from samples including veterinary samples, clinical samples, food samples, forensic sample, an environmental sample (e.g., soil, dirt, garbage, sewage, air, or water), including food processing and manufacturing surfaces, or a biological sample.
Absstract of: US2025333809A1
Disclosed are oligonucleotide primers that hybridize specifically with any base sequence designed from the base sequences of the N gene, RNA-dependent RNA polymerase gene, M gene, and S gene of SARS-COV-2, a nucleic acid amplification method using said primers, a test method for SARS-COV-2 infection by detection of nucleic acid amplification, and a COVID-19 test kit.
Absstract of: WO2025225632A1
The purpose of the present invention is to provide an antiviral agent effective against COVID-19. The purpose can be achieved by (1) a polypeptide that contains an amino acid sequence selected from the group consisting of the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, and the amino acid sequence represented by SEQ ID NO: 8, or (2) a polypeptide that has antiviral activity against coronavirus, contains an amino acid sequence in which one amino acid is substituted in the amino acid sequence represented by SEQ ID NO: 1, the amino acid sequence represented by SEQ ID NO: 2, the amino acid sequence represented by SEQ ID NO: 3, the amino acid sequence represented by SEQ ID NO: 4, the amino acid sequence represented by SEQ ID NO: 5, the amino acid sequence represented by SEQ ID NO: 6, the amino acid sequence represented by SEQ ID NO: 7, or the amino acid sequence represented by SEQ ID NO: 8, said polypeptide having an O-glycoside-linked sugar chain.
Absstract of: WO2024137381A1
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies. In some aspects, the antibodies bind a BA.4 or BA.5 variant. In other aspects, the antibodies bind BQ1.1 and/or XBV.
Absstract of: WO2024133564A1
: SARS-CoV-2 spike protein-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the SARS-CoV-2 spike protein-binding molecules.
Absstract of: ZA202500860B
Provided are a pharmaceutical composition for resisting infection with SARS-CoV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-CoV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-CoV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-CoV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.
Absstract of: EP4640230A1
An application of Shenling Baizhu in the preparation of a medicine for treating neuropsychiatric symptoms of recovered COVID-19 patients.
Absstract of: EP4641196A1
Disclosed is a CRISPR/Cas based system for screening an RNA aptamer against a target protein, comprising: (i) a guide RNA comprising a recognition sequence and a nucleic acid aptamer random library having a predetermined length; (ii) a target sequence complementary to the recognition sequence of the guide RNA; (iii) a selection marker located downstream of the target sequence and comprising a basal promoter and a selection marker gene; (iv) a fusion protein comprising the target protein and a transcriptional activation module, wherein a binding of the target protein to an RNA aptamer of the nucleic acid aptamer random library results in recruitment of the transcriptional activation module to the selection marker; (v) a dCas protein specifically recognizing the target sequence under the guidance of the guide RNA; and (vi) a screening cell. Also disclosed is a method for screening an RNA aptamer against a target protein using the system provided herein and RNA aptamers against S1 protein of SARS-CoV-2 virus and applications thereof.
Absstract of: CN120842372A
The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR39 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR39 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR39 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR39 has high affinity and dilution stability and is suitable for clinical large-dose administration.
Absstract of: KR20250153936A
본 발명은 페이퍼 멤브레인 기반 현장 진단용 DNA 또는 RNA 추출 키트에 관한 것으로, 측방 유동 분리 방식을 기반으로, 짧은 시간 내에 효율적으로 다양한 종류의 샘플들로부터 DNA 또는 RNA 추출이 가능한 DNA 또는 RNA 추출 디바이스로서, 표적 바이러스 검출을 위한 페이퍼 멤브레인 기반 현장용 DNA 또는 RNA 추출 플랫폼을 제공할 수 있다.
Absstract of: CN120858106A
The invention discloses a short and small polypeptide capable of inhibiting beta human coronavirus from invading host cells in a broad-spectrum manner and a medicinal application of the short and small polypeptide. Reasonable drug design is carried out based on the universality and conservative property of the six-strand alpha-helix bundle (6-HB) structure of coronavirus spike protein in the process that beta human coronavirus enters host cells. According to the present invention, alpha helical conformation restriction is performed on an HR2 structure domain derived polypeptide in 6-HB, such that a short and small polypeptide having a broad-spectrum inhibition effect on infection of two or more beta human coronaviruses (such as SARS-CoV, MERS-CoV, SARS-CoV-2, OC43) is provided. The polypeptide has the important advantages of being high in antiviral activity, short in sequence, easy to synthesize and the like. Candidate drug reserve and technical reserve are proactively provided for research and development of emergency prevention and control drugs for new and reproduced human coronavirus infection epidemic situations in the future.
Absstract of: CN120842985A
The invention belongs to the technical field of antibacterial and antiviral materials, and particularly relates to a long-acting antibacterial and antiviral nano ceramic coating as well as a preparation method and application thereof. The nano ceramic coating provided by the invention comprises 25-30% of methoxytrimethylsilane, 1-5% of organosilicon quaternary ammonium salt, 20-30% of nano silicon dioxide sol, 0.5-1% of a catalyst, 1-2% of a protective agent, the balance of deionized water and the like. Compared with silver, copper, titanium and the like, the modified space is large, and compared with common quaternary ammonium salt materials, bacteria are not prone to evolving drug resistance. According to the invention, O-Si-O is taken as a main body to form a 3D net-shaped structure, through an anchor gun strategy, huge flexibility and a modification space are provided for a material structure, and efficient and rapid sterilization is realized. Tests on eight moulds and two viruses confirm that the nano ceramic coating belongs to a long-acting antibacterial and antiviral self-disinfection nano ceramic coating, and the mould resistance, enterovirus resistance and novel coronavirus resistance of the material are proved.
Absstract of: LU601360B1
A Chinese medicine formula for COVID-19, comprising the following raw materials by weight ratio: 25 grams of siraitia grosvenorii flower, 10 grams to 20 grams of ligustrum lucidum, 5 grams to 10 grams of winter mulberry leaves, 8 grams to 15 grams of Chinese mahonia, 5 grams to 10 grams of Dizhu leaves, 5 grams to 10 grams of gardenia jasminoides, 3 grams to 8 grams of astragalus membranaceus, 3 grams to 8 grams of gentiana, 5 grams to 10 grams of ophiopogon japonicus, 2 grams to 6 grams of cassia twig, 3 grams to 8 grams of artemisia argyi leaves, and 10 grams to 15 grams of hairy holly. Based on the in-depth analysis of the pathogenesis characteristics of COVID-19, the invention achieves a comprehensive improvement of the symptoms of the COVID-19 by reasonable compatibility of a variety of Chinese medicinal materials; wherein, the combination of siraitia grosvenorii flower and ligustrum lucidum significantly improves the symptoms of dry throat and cough; winter mulberry leaves and Chinese mahonia can synergistically reduce fever quickly; the invention is suitable for various symptoms such as headache, fever, sore throat, chest tightness, cough (dry cough) caused by the COVID-19; generally, it turns from positive to negative in 3 to 4 days, and it takes 5 days to 8 days to eliminate all the symptoms mentioned hereinabove, depending on the physical condition of each person.
Absstract of: CN120837493A
The invention discloses an application of a Fascin protein inhibitor in virus infection resistance. Specifically, the invention discloses an application of a small molecule drug NP-G2-044, and the small molecule drug NP-G2-044 is used for preparing a drug preparation or a composition for resisting virus infection. According to the NP-G2-044 disclosed by the invention, the formation of filopodia clamped by a virus is inhibited, so that the novel coronavirus is prevented from entering a host cell through the filopodia, and the virus infection is effectively controlled.
Absstract of: CN120837599A
The invention provides a traditional Chinese medicine composition and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition capable of being used for treating novel coronavirus infection is obtained by taking Maxingshigan decoction and Yinqiao powder as the basis and simultaneously combining black nightshade herb, scourge-clearing toxin-vanquishing decoction, agastache rugosus stomach-clearing pills, vitex negundo-defatted toxin-vanquishing decoction, elsholtzia ciliata decoction, immature bitter orange, allium macrostemon and cassia twig decoction and magnolia flower rhinitis pills. The traditional Chinese medicine composition has the effects of resisting viruses, resisting inflammation and regulating immunity, and can inhibit virus replication in an extremely short time, so that the disease resistance of the body of a patient is quickly enhanced, and the body is completely recovered to be healthy and does not relapse.
Absstract of: CN120842330A
The invention relates to a polypeptide RFTT and application of the polypeptide RFTT in preparation of a novel coronavirus resisting drug, belongs to the technical field of antiviral drugs, and provides the polypeptide RFTT, and the amino acid sequence of the polypeptide RFTT is HLYVSPWGGFLNRFTTTLNDFN; meanwhile, a cell-penetrating peptide sequence capable of penetrating cell membranes is added to the N end of the amino acid sequence of the polypeptide. The polypeptide can competitively inhibit phosphorylation of AKT-mediated new coronavirus main protease (Mpro), promote degradation of Mpro and inhibit virus replication. Besides, the polypeptide RFTT has the characteristics of strong target spot conservative property and high antiviral activity, and shows a remarkable new coronavirus variant resisting effect in an in-vitro Vero cell infection model, and the maximum median inhibitory concentration (IC50) for inhibiting replication of a new coronavirus wild strain is 0.034 mu M. Therefore, the polypeptide provided by the invention provides a new strategy for developing anti-new coronavirus drugs.
Nº publicación: US12453717B1 28/10/2025
Applicant:
ACCENCIO LLC [US]
ACCENCIO LC [US]
Accencio LLC,
Accencio LC
Absstract of: US12453717B1
The present disclosure relates to a method of reducing or arresting viral load in a subject infected with a coronavirus, the method comprising the step of administering to the subject a therapeutically effective amount of a viral protease inhibitor. In some embodiments, the subject is a human. In one embodiment, the coronavirus is SARS-CoV-19 and the viral protease inhibitor is frovatriptan (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide.
BOPI
Electronic site
